Proactive Investors - Run By Investors For Investors

Motif BIo chief “very confident” for Phase III iclaprim trial

Graham Lumsden, chief executive of Motif Bio (LON:MTFB), says he is “very confident” in the firm’s Phase III study for its next-generation antibiotic, iclaprim.

The firm passed a major milestone when it dosed its first patient in one of two phase III clinical trials on Wednesday.

Lumsden says it is a “huge accomplishment by the team at Motif,” and “great news for shareholders”.

The studies, which will assess the drug’s potential in treating acute bacterial skin and skin structure infection, will look at efficacy and safety and compare them with the standard treatment vancomycin.

Meet Sayona Mining Ltd, Lithium Power International Ltd, Elementos, Tyranna Resources and Argent Minerals Ltd at our event, Melbourne, 25 July 2017. Register here »
View full MTFB profile View Profile

Motif Bio Plc Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use